Prospecta / Materia Medica - LARVOL DELTA

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries (clinicaltrials.gov) - P3 | N=246 | Completed | Sponsor: Materia Medica Holding | Active, not recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Feb 2023 | Trial primary completion date: Jul 2023 ➔ Feb 2023

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Ischemic stroke

Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia. (clinicaltrials.gov) - P3 | N=406 | Completed | Sponsor: Materia Medica Holding | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Sep 2022 | Trial primary completion date: Dec 2023 ➔ Sep 2022

Trial completion • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation • Psychiatry

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries (clinicaltrials.gov) - P3 | N=246 | Active, not recruiting | Sponsor: Materia Medica Holding | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Dec 2022 ➔ Jul 2023

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Ischemic stroke

Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children (clinicaltrials.gov) - P3 | N=366 | Completed | Sponsor: Materia Medica Holding | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Feb 2022 | Trial primary completion date: Dec 2022 ➔ Feb 2022

Trial completion • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia. (clinicaltrials.gov) - P3 | N=406 | Active, not recruiting | Sponsor: Materia Medica Holding | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation • Psychiatry

Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children (clinicaltrials.gov) - P3 | N=366 | Active, not recruiting | Sponsor: Materia Medica Holding | Recruiting ➔ Active, not recruiting

Enrollment closed • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders (clinicaltrials.gov) - P3; N=246; Recruiting; Sponsor: Materia Medica Holding; Suspended ➔ Recruiting

Clinical • Enrollment open • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Ischemic stroke

Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children (clinicaltrials.gov) - P3; N=366; Recruiting; Sponsor: Materia Medica Holding; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia. (clinicaltrials.gov) - P3; N=406; Recruiting; Sponsor: Materia Medica Holding; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation • Psychiatry

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders (clinicaltrials.gov) - P3; N=246; Suspended; Sponsor: Materia Medica Holding; Recruiting ➔ Suspended

Clinical • Trial suspension • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Ischemic stroke

Clinical Trial of Efficacy and Safety of Prospecta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children (clinicaltrials.gov) - P3; N=366; Not yet recruiting; Sponsor: Materia Medica Holding

Clinical • New P3 trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry